Tesamorelin (Egrifta SV): Evidence, Side Effects, and Regulatory Status (2026)
Tesamorelin (Egrifta SV) is FDA-approved. Evidence grade: strong. This page is clinically reviewed.
TL;DR / Quick Facts
Tesamorelin (Egrifta SV) is Tesamorelin is a stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in adult patients with HIV-associated lipodystrophy. Marketed as Egrifta SV. FDA status: FDA-approved. Typical use cases: longevity, mens health, fat loss. Evidence grade: strong. Dosing is per the FDA label — set by your clinician. Common side effects: see below. Medriva editorial stance: follow the FDA label; do not use off-label without clinical supervision.
What it is
Tesamorelin (Egrifta SV) is a member of the GHRH analog class. Tesamorelin binds the GHRH receptor on the anterior pituitary, stimulating growth hormone release and downstream IGF-1. The 'stabilized' formulation (SV) provides a longer half-life than the original Egrifta.
What the evidence says
Evidence for Tesamorelin (Egrifta SV) is strong. Multiple phase 3 trials and post-market data support the labeled indications.
[Detailed evidence breakdown in the corresponding claim or pillar pages is linked at the bottom of this page.]
What it's used for
Commonly discussed uses of Tesamorelin (Egrifta SV):
- Longevity — strong evidence.
- Additional uses listed in the linked use-case hubs; evidence varies by indication.
For the full list, see the linked use-case hubs below.
Typical dosing
Tesamorelin dosing is determined by the approved label, indication, comorbidities, current medications, and clinician judgment. Medriva does not publish individualized dosing instructions or titration schedules. Review the current prescribing information and make changes only with a licensed clinician.
Side effects and risks
- Common: Side effects vary by compound and indication; review the approved label or profile-specific safety data with a clinician.
- Serious: Seek urgent care for severe allergic symptoms, chest pain, severe abdominal pain, persistent vomiting, or other severe reactions.
- Long-term unknowns: For non-approved or research-use compounds, long-term human safety data may be limited.
Regulatory status
- FDA-approved use(s): Egrifta SV (HIV-associated lipodystrophy).
- Compounded availability: see 503A vs 503B explainer
- Research-use-only (RUO) availability: n/a
- Banned in sport: see WADA & sports explainer
Cost and access
Tesamorelin (Egrifta SV) is available by prescription; see the cost page for the relevant indication. For pricing, see our cost pages or the GLP-1 price/supply tracker where applicable.
Who it might be appropriate for
Adults with a relevant diagnosed condition or clinical goal, under the supervision of a licensed clinician, who have no contraindications. Tesamorelin (Egrifta SV) is not for self-experimentation.
Who should not use it
Contraindications vary by compound, indication, pregnancy status, comorbidities, and current medications. For the full list, see the contraindications checklist and discuss with your clinician.
Medriva editorial stance
We describe the literature. We do not promote Tesamorelin (Egrifta SV) as a cure, treatment, or performance enhancer. We do not recommend it for self-experimentation. We do recommend that readers (a) understand the evidence grade (strong), (b) understand the regulatory status (FDA-approved), and (c) discuss with a licensed clinician before acting.
How to talk to a clinician
See our guide on how to talk to a clinician for a templated conversation.
Frequently Asked Questions
Is Tesamorelin (Egrifta SV) FDA-approved?
FDA-approved. See the regulatory status section above for details.
Does Tesamorelin (Egrifta SV) work for longevity?
Evidence is strong. See the linked use-case hub for the full breakdown.
What are the side effects?
See the side effects section above. Discuss with your clinician.
How much does Tesamorelin (Egrifta SV) cost?
See the cost pages or the GLP-1 price/supply tracker where applicable.
Can I buy Tesamorelin (Egrifta SV) online?
By prescription only. Medriva does not sell peptides.
Author + Clinical reviewer
Author: Priya Menon, MS Clinical reviewer: Jonathan Reeves, MD Last reviewed: 2026-06-05
Next steps
- Review the evidence grade and regulatory status before making decisions about Tesamorelin.
- Bring this page to a licensed clinician if you are discussing benefits, risks, or alternatives.
- Subscribe to the Medriva Peptide Brief for evidence and regulatory updates.
Related use-case hubs
Related comparisons
Editorial process
This page follows the Medriva Editorial Policy and the Clinical Review Methodology. Page last reviewed: 2026-06-05. Author: Priya Menon, MS. Clinical reviewer: Jonathan Reeves, MD.
Current source updates
For new regulator actions, compounding-policy changes, warning letters, shortage updates, and sports-rule changes, review the Peptide Tracker before relying on older summaries.
